<DOC>
	<DOCNO>NCT02198664</DOCNO>
	<brief_summary>This multi-center , open-label , follow-on study gather additional information safety tolerability oral desensitization CPNA subject participate ARC001 .</brief_summary>
	<brief_title>Oral Desensitization Peanut Peanut Allergic Children Adults Using ( CPNA ) Peanut OIT Safety Follow-On Study</brief_title>
	<detailed_description>All subject receive daily oral dose peanut OIT ( oral immunotherapy ) form Characterized Peanut Allergen ( CPNA ) . Study Duration - 12-90 week reach Extended Maintenance Phase . All Subjects may continue Extended Maintenance Phase CPNA become commercially available study terminate .</detailed_description>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Completion ARC001 study Use birth control females childbearing age No change status longitudinally applicable ARC001 inclusion criterion Early termination ARC001 Failure tolerate 300 mg peanut protein ARC001 exit food challenge A lapse dose 10 day completion ARC001 Change status longitudinally applicable ARC001 exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Characterized Peanut Allergen</keyword>
	<keyword>Peanut</keyword>
	<keyword>OIT</keyword>
	<keyword>Oral Desensitization</keyword>
	<keyword>Peanut Allergen</keyword>
	<keyword>Peanut-Allergic Children</keyword>
	<keyword>Children</keyword>
	<keyword>Peanut-Allergic Adults</keyword>
</DOC>